Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)

NCT04716452 is registered in ClinicalTrials.gov with Keystone Nano, Inc as lead sponsor.

NCT NCT04716452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04716452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)
Lead sponsor
Keystone Nano, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
October 1, 2025
Completion date
November 30, 2026
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, in relapse, acute myeloid leukemia, refractory, refractory/relapse acute myeloid leukemia